MNPR vs NEM · $431.4M cap vs P/E 14, rev $13.43B
Monopar Therapeutics Inc (MNPR) versus Newmont Goldcorp Corp (NEM) — a side-by-side from cached financials, not a winner call.
Monopar Therapeutics Inc (MNPR) is a biotechnology company listed on US.
Newmont Goldcorp Corp (NEM) is a gold company listed on NYSE.
Latest reported MNPR revenue for 2026-06-30 was $0. Net income was -$9.2M. MNPR currently screens at market cap $431.4M.
Latest reported NEM revenue for 2026-06-30 was $13.43B. Net income was $5.46B. Revenue was up 83.7% from 2026-03-31 to 2026-06-30. NEM currently screens at market cap $112.81B and trailing P/E 13.7.
MNPR currently screens at market cap $431.4M. NEM currently screens at market cap $112.81B and trailing P/E 13.7.
Not investment advice. Open the MNPR and NEM stock pages for the full models.
Not investment advice.